Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04804605 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1220

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis Eczema

Interventions

DRUG: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%

Sponsor

Arcutis Biotherapeutics, Inc.